Nuwellis, Inc. (NUWE) — SEC Filings
Nuwellis, Inc. (NUWE) — 50 SEC filings. Latest: 4 (Apr 30, 2026). Includes 33 8-K, 4 10-Q, 3 S-1.
View Nuwellis, Inc. on SEC EDGAR
Overview
Nuwellis, Inc. (NUWE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 6, 2026: Nuwellis, Inc. filed a Definitive Additional Materials (DEFA14A) on April 6, 2026, related to proxy solicitations. The filing provides additional information for shareholders concerning matters to be voted on at a company meeting. Specific details regarding the proposals or resolutions are not inclu
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 8 bearish, 41 neutral. The dominant filing sentiment for Nuwellis, Inc. is neutral.
Filing Type Overview
Nuwellis, Inc. (NUWE) has filed 1 4, 1 DEFA14A, 1 ARS, 4 10-Q, 33 8-K, 2 DEF 14A, 2 S-1/A, 3 S-1, 1 10-K, 2 SC 13G with the SEC between May 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of NUWE's 47 recent filings, 8 were flagged as high-risk, 26 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $5.846M |
| Net Income | $(15.099M) |
| EPS | N/A |
| Debt-to-Equity | 1.04 |
| Cash Position | $3.094M |
| Operating Margin | N/A |
| Total Assets | $7.984M |
| Total Debt | $4.070M |
Key Executives
- Chief Executive Officer
- Minneapolis
- Board of Directors
- John L. Erb
- Phillip D. Torrence, Esq.
- Jessica M. Herron, Esq.
- N. Danny Shulman, Esq.
- Neil P. Ayotte
- Michael F. Nertney, Esq.
- Nestor Jaramillo, Jr.
Industry Context
Nuwellis operates in the medical device sector, specifically focusing on solutions for heart failure. This industry is characterized by high R&D costs, stringent regulatory hurdles (FDA approval), and a competitive landscape with established players and emerging technologies. The demand for innovative treatments for chronic conditions like heart failure remains strong, but companies face challenges in market adoption and reimbursement.
Top Tags
regulatory-filing (7) · material-agreement (7) · 8-K (6) · filing (6) · corporate-governance (6) · sec-filing (5) · equity-sale (4) · company-update (3) · 8-k (3) · Medical Technology (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income (Q3 2025) | $468K | Down from $2.358M in Q3 2024, indicating a significant decline in profitability. |
| Net loss (YTD Q3 2025) | $(15.099M) | Widened from $(9.697M) in YTD Q3 2024, showing increasing losses over the year. |
| Net sales (Q3 2025) | $2.217M | Decreased from $2.367M in Q3 2024, reflecting a decline in product demand or market share. |
| Net sales (YTD Q3 2025) | $5.846M | Decreased from $6.418M in YTD Q3 2024, indicating a sustained downward trend in revenue. |
| Cash and cash equivalents (Sept 30, 2025) | $3.094M | Decreased from $5.095M at Dec 31, 2024, highlighting significant cash burn. |
| Accumulated deficit (Sept 30, 2025) | $313.9M | Indicates substantial historical losses and raises 'going concern' doubts. |
| Common Stock shares outstanding (Nov 7, 2025) | 1,658,799 | Increased significantly from 104,142 at Dec 31, 2024, suggesting substantial dilution. |
| Reduction in monthly cash burn rate (2024) | 40% | Company undertook measures to reduce expenses, but still faces capital needs. |
| Capital runway | Q1 2026 | Existing capital resources are only sufficient to support operations into the first quarter of 2026. |
| Selling, general and administrative expenses (Q3 2025) | $3,539K | Increased from $2,702K in Q3 2024, contributing to operating losses. |
| SEC File Number | 001-35312 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 68-0533453 | Company's tax identification number. |
| EIN | 680533453 | Employer Identification Number for tax purposes. |
| Central Index Key | 0001506492 | Unique identifier for the filer in the SEC EDGAR system. |
| Net loss (Q2 2025) | $12.553M | Increased from $7.725 million in Q2 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Nuwellis, Inc. (NUWE)?
Nuwellis, Inc. has 50 recent SEC filings from May 2024 to Apr 2026, including 33 8-K, 4 10-Q, 3 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NUWE filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 8 bearish, 41 neutral. The dominant sentiment is neutral.
Where can I find Nuwellis, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nuwellis, Inc. (NUWE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nuwellis, Inc.?
Key financial highlights from Nuwellis, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NUWE?
The investment thesis for NUWE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nuwellis, Inc.?
Key executives identified across Nuwellis, Inc.'s filings include Chief Executive Officer, Minneapolis, Board of Directors, John L. Erb, Phillip D. Torrence, Esq. and 5 others.
What are the main risk factors for Nuwellis, Inc. stock?
Of NUWE's 47 assessed filings, 8 were flagged high-risk, 26 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Nuwellis, Inc.?
Forward guidance and predictions for Nuwellis, Inc. are extracted from SEC filings as they are enriched.